A 52-year-old woman with chronic obstructive pulmonary disease (COPD) on regular tiotropium (long-acting muscarinic antagonist) and salbutamol reports persistent dyspnea on exertion despite compliance. Her physician suspects inadequate bronchodilation and wants to objectively assess the degree of airway obstruction and response to additional bronchodilator therapy. Which investigation is most appropriate to guide further therapeutic escalation?

Explanation

## Investigation of Choice for COPD Severity Assessment and Bronchodilator Response ### Post-Bronchodilator Spirometry with GOLD Classification **Key Point:** Post-bronchodilator spirometry is the gold standard investigation to assess COPD severity, quantify airway obstruction, and guide bronchodilator therapy escalation according to GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines. **High-Yield:** COPD severity is classified by post-bronchodilator FEV₁ as a percentage of predicted: - **GOLD 1 (Mild):** FEV₁ ≥80% predicted - **GOLD 2 (Moderate):** 50–79% predicted - **GOLD 3 (Severe):** 30–49% predicted - **GOLD 4 (Very Severe):** <30% predicted ### Clinical Application in This Case 1. **Baseline spirometry** — measure current FEV₁ to assess obstruction severity 2. **SABA or LABA administration** — assess bronchodilator response 3. **Post-bronchodilator FEV₁** — defines irreversible obstruction component 4. **GOLD ABCD classification** — incorporates FEV₁ + symptom burden + exacerbation history to guide therapy escalation **Clinical Pearl:** In COPD, unlike asthma, the bronchodilator response is typically <12% improvement in FEV₁, but post-bronchodilator FEV₁ is still the reference standard for severity staging and treatment decisions. ### Why This Test for Therapy Escalation? - **Objective quantification** of residual airway obstruction - **Guides LABA/LAMA combination therapy** — if FEV₁ still low despite monotherapy - **Identifies need for triple therapy** (LABA + LAMA + ICS) in severe COPD - **Prognostic stratification** — correlates with exacerbation risk and mortality **Mnemonic: GOLD FERN** — FEV₁ (post-bronchodilator), Exacerbation history, Respiratory symptoms, Number of agents needed. [cite:KD Tripathi 8e Ch 15]